- Trial phase
- Approved
- Time to market
- Already approved and marketed (OTC since March 2023).
- Why 4/10
- NARCAN is already approved and commercialized with no pending PDUFA date or pivotal readout scheduled in the next ~12 months. The defining binary (OTC approval in March 2023) has passed. ImpactScore is 4 because while NARCAN is a major product for Emergent, the commercial trajectory (declining sales from competition) is not a hard binary catalyst.
Watch for continued erosion of NARCAN market share as three OTC competitors (RiVive, Rextovy, and Amneal's generic) intensify pricing pressure. Emergent's Q3 2026 earnings (Nov 2) showed naloxone revenue down 42% YoY, and the company cut full-year guidance. The next major catalyst is the Q4 2026 earnings report in early 2027, which will show whether the multipack strategy and Canadian expansion can offset U.S. market share losses.
Price Chart
Executive Summary
NARCAN (naloxone HCl nasal spray 4 mg) is Emergent BioSolutions' over-the-counter opioid overdose reversal product, first approved by the FDA in 2015 (prescription) and switched to OTC in March 2023 as the first nonprescription naloxone product. While NARCAN was a first-mover in the OTC space, it now faces at least three OTC competitors (RiVive, Rextovy/Amphastar, and Amneal's generic), driving aggressive pricing pressure. Naloxone revenue fell 42% YoY in Q3 2026, and Emergent recorded a $191.3M impairment on the NARCAN asset group in Q2 2026. The stock fell ~25% in after-hours trading on Nov 2, 2026 after reporting Q3 results and cutting full-year guidance. NARCAN is already approved with no upcoming binary regulatory catalysts.
How It Works
NARCAN (naloxone) is an opioid antagonist that rapidly reverses the effects of an opioid overdose by binding to opioid receptors in the brain and blocking or displacing opioids like heroin, fentanyl, or prescription painkillers. It is administered as a nasal spray and can restore normal breathing within minutes in a person whose breathing has slowed or stopped due to an opioid overdose.
Trial Status
NARCAN is an FDA-approved, commercially marketed product. Supplemental NDAs for new carrying case packaging (January 2026) and multipack configurations (February 2026) were approved. No clinical trials are ongoing for the approved formulation.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 / full-year 2026 earnings report (early 2027) - will show whether NARCAN revenue decline is stabilizing or accelerating
- Further competitive dynamics as additional OTC naloxone entrants potentially launch
- Any further label expansion or packaging sNDA approvals
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Emergent BioSolutions Inc. 8-K EBS ·Originating report